Soluble angiopoietin receptor Tie-2 in patients with acute myocardial infarction and its effects on angiogenesis

Clinical Hemorheology and Microcirculation

Volumn 33, Issue 1, 2005, Pages 1-10

  Wang, Chunling ^a   Fu, Panfeng ^a   Li, Hongwei ^a   Gao, Runlin ^a   Xiu, Ruijuan ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Chinese Academy of Medical Sciences   (China)

Author keywords

Acute myocardial infarction; Angiogenesis; Recombinant soluble Tie 2 Fc chimera; Soluble Tie 2

Indexed keywords

ANGIOPOIETIN RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL VIABILITY; CHIMERA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PROTEIN BLOOD LEVEL; THORAX PAIN; UMBILICAL VEIN;

AGED; CASE-CONTROL STUDIES; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, TIE-2; RECOMBINANT PROTEINS; SOLUBILITY; TIME FACTORS; UMBILICAL VEINS;

EID: 22744443059     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. W. Schaper and I. Buschmann, Arteriogenesis, the good and bad of it, Cardiovasc. Res. 43 (1999), 835-837.
2. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto and J.E. Park, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N. Engl. J. Med. 331 (1994), 1480-1487.
3. D.C. Felmeden, A.D. Blann and G.Y. Lip, Angiogenesis: basic pathophysiology and implications for disease, Eur. Heart J. 24 (2003), 586-603.
4. K.H. Plate, G. Breier, H.A. Weich and W. Risau, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature 359 (1992), 845-848.
5. G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand and J. Holash, Vascular-specific growth factors and blood vessel formation, Nature 407 (2000), 242-248.
6. T.N. Sato, Y. Tozawa, U. Deutsch, K. Wolburg-Buchholz, Y. Fujiwara, M. Gendron-Maguire, T. Gridley, H. Wolburg, W. Risau and Y. Qin, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation, Nature 376 (1995), 70-74.
7. D.M. Valenzuela, J.A. Griffiths, J. Rojas, T.H. Aldrich, P.F. Jones, H. Zhou, J. McClain, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, T. Huang, N. Papadopoulos, P.C. Maisonpierre, S. Davis and G.D. Yancopoulos, Angiopoietins 3 and 4: diverging gene counterparts in mice and humans, Proc. Natl. Acad. Sci. USA 96 (1999), 1904-1909.
8. D. Hanahan, Signaling vascular morphogenesis and maintenance, Science 277 (1997), 48-50.
9. M.C. Puri, J. Partanen, J. Rossant and A. Bernstein, Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development, Development 126 (1999), 4569-4580.
10. J. Holash, S.J. Wiegand and G.D. Yancopoulos, New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF, Oncogene 18 (1999), 5356-5362.
11. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos and S.J. Wiegan, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science 284 (1999), 1994-1998.
12. A.T. Baron, J.M. Lafky, C.H. Boardman, S. Balasubramaniam, V.J. Suman, K.C. Podratz and N.J. Maihle, Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Cancer Epidemiol. Biomarkers Prev. 8 (1999), 129-137.
13. P. Reusch, B. Barleon, K. Weindel, G. Martiny-Baron, A. Godde, G. Siemeister and D. Marme, Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood, Angiogenesis 4 (2001), 123-131.
14. E.A. Jaffe, R.L. Nachman, C.G. Becker and C.R. Minick, Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria, J. Clin. Invest. 52 (1973), 2745-2756.
15. R. Donnelly and J.M. Yeung, Therapeutic angiogenesis: a step forward in intermittent claudication, Lancet 359 (2002), 2048-2050.
16. A.C. Barger, R. Beeuwkes, L.L. Lainey and K.J. Silverman, Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis, N. Engl. J. Med. 310 (1984), 175-177.
17. E.R. O'Brien, M.R. Garvin, R. Dev, D.K. Stewart, T. Hinohara, J.B. Simpson and S.M. Schwartz, Angiogenesis in human coronary atherosclerotic plaques, Am. J. Pathol. 145 (1994), 883-894.
18. H.F. Dvorak, L.F. Brown, M. Detmar and A.M. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am. J. Pathol. 146 (1995), 1029-1039.
19. F. Jung, R.P. Franke, C. Mrowietz, S. Wolf and H. Kiesewetter, Capillary occlusion and secondary angiogenesis in a patient with Raynaud's phenomenon, J. Vasc. Res. 29 (1992), 71-74.
20. D. Scholz, W.J. Cai and W. Schaper, Arteriogenesis, a new concept of vascular adaptation in occlusive disease, Angiogenesis 4 (2001), 247-257.
21. H. El-Gendi, A.G. Violaris, R. Foale, H.S. Sharma and D.J. Sheridan, Endogenous, local, vascular endothelial growth factor production in patients with chronic total coronary artery occlusions: further evidence for its role in angiogenesis, Heart 87 (2002), 158-159.
22. S.B. Freedman and J.M. Isner, Therapeutic angiogenesis for coronary artery disease, Ann. Intern. Med. 136 (2002), 54-71.
23. C.H. Lee and P. Smits, Vascular growth factors for coronary angiogenesis, J. Interven. Cardiol. 15 (2002), 511-518.
24. C. Suri, P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, S. Davis, T.N. Sato and G.D.Yancopoulos, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis, Cell 87 (1996), 1171-1180.
25. D.J. Dumont, G. Gradwohl, G.H. Fong, M.C. Puri, M. Gertsenstein, A. Auerbach and M.L. Breitman, Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo, Genes Dev. 8 (1994), 1897-1909.
26. J.M. Isner and T. Asahara, Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization, J. Clin. Invest. 103 (1999), 1231-1236.
27. P.S. Ray, T. Estrada-Hernandez, H. Sasaki, L. Zhu and N. Maulik, Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis, Mol. Cell Biochem. 213 (2000), 145-153.
28. A.L. Harris, P. Reusch, B. Barleon, C. Hang, N. Dobbs and D. Marme, Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy, Clin. Cancer Res. 7 (2001), 1992-1997.
29. N.A. Chung, A.J. Makin and G.Y. Lip, Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay, Eur. J. Clin. Invest. 33 (2003), 529-535.
30. P. Lin, P. Polverini, M. Dewhirst, S. Shan, P.S. Rao and K. Peters, Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth, J. Clin. Invest. 100 (1997), 2072-2078.
31. P. Lin, S. Sankar, S. Shan, M.W. Dewhirst, P.J. Polverini, T.Q. Quinn and K.G. Peters, Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor, Cell Growth Differ. 9 (1998), 49-58.
32. H.F. Alber, J. Dulak, M. Frick, W. Dichtl, S.P. Schwarzacher, O. Pachinger and F. Weidinger, Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease, J. Am. Coll. Cardiol. 39 (2002), 1951-1955.